BMYClinical Trials•businesswire•
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
Sentiment:Positive (80)
Summary
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #18ICML--BMS Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 16, 2025 by businesswire